Gynecologic Oncology Clinical Trials
Central to the department’s mission of providing exceptional research-driven care is the development of clinical research trials, including prevention trials, innovative surgical trials and therapeutic trials. The following is a list of ongoing major therapeutic trials.
Central to the department’s mission of providing exceptional research-driven care is the development of clinical research trials, including prevention trials, innovative surgical trials and therapeutic trials. The following is a list of ongoing major therapeutic trials.
Jump to a section:
Clinical trials by disease site
Ovarian
Neoadjuvant therapy
2022-0451 (Imunon): A phase II study evaluating the effect of GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) on second look laparoscopy (SLL) when administered in combination with Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in subjects newly diagnosed with advanced ovarian, fallopian tube or primary peritoneal cancer.
Post-Completion of Primary Therapy
2022-0685 (PCB): Phase II investigation of Pembrolizumab in combination with Bevacizumab and Oral Cyclophosphamide in patients with high grade ovarian cancer and surgically documented minimal residual disease after frontline therapy.
Recurrent - Platinum Sensitive
2024-0507 (Anti-CD40 CDX-1140): Randomized phase II clinical trial of Pembrolizumab combined with Bevacizumab with or without Agonist Anti-CD40 CDX-1140 in patients with recurrent ovarian cancer.
Recurrent - Platinum Resistant
2022-0231 (Lurbi, Taxol, Bev): Phase 1b of lurbinectedin in combination with weekly paclitaxel and bevacizumab in platinum-resistant ovarian cancer.
2023-0585 (Combo MATCH): EAY191-N4: A randomized trial of Selumetinib and Olaparib or Selumetinib alone in patients with recurrent or persistent Ras pathway mutant Ovarian and Endometrial cancers.
2022-0687 (TROP2): Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer.
2024-0507 (Anti-CD40 CDX-1140): Randomized phase II clinical trial of Pembrolizumab combined with Bevacizumab with or without Agonist Anti-CD40 CDX-1140 in patients with recurrent ovarian cancer.
2024-2001 (MacroGenics): A phase II multicohort study to evaluate Lorigerlimab in patients with advanced solid tumors.
2024-1422 (LOXO): A study of LY4170156 in patients with selected advanced solid tumors.
2024-15500 (GOG-3096) REJOICE: A study of Deruxtecan (R-DXd), a CDH6-directed antibody-drug conjugate, in patients with platinum-resistant, high-grade ovarian, primary peritoneal or fallopian tube cancer.
2025-0424 Outpace Bio (MSLN) CAR: A phase 1a/b study to evaluate the safety and efficacy of OPB-101, an autologous mesothelin (MSLN) CAR T cell therapy with antigen-dependent expression of OUTSMART™ designed IL-2 cytokine in platinum-resistant ovarian cancer.
2024-1939 (DENALI): A phase II open-label, multicenter study to evaluate efficacy and safety of ZN.c3 in patients with high-grade serous ovarian, fallopian tube or primary peritoneal cancer.
Rare Tumors (Ovarian)
Low-Grade serous, primary
2024-0475 (GOG 3097) - RAMP: A phase III, randomized, open-label study of combination therapy with Avutometinib plus Defactinib versus investigator's choice in treatment in patients with recurrent Low-Grade Serous Ovarian Cancer (LGSOC).
Clear-cell, recurrent
2022-1047 (Dostarlimab, LB-100): Safety and efficacy of targeting PP2A in ovarian clear cell carcinoma using Dostarlimab and LB-100.
2024-2011 (MacroGenics): A phase II multicohort study to evaluate Lorigerlimab in participants with advanced solid tumors.
2024-0507 (Anti-CD40 CDX-1140): A randomized phase II clinical trial of Pembrolizumab combined with Bevacizumab with or without agonist anti-CD40 CDX-1140 in patients with recurrent ovarian cancer.
Recurrent Mucinous
2021-0660 (HIPEC) Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study).
Endometrial (Uterine)
Primary Therapy (Newly Diagnosed, Untreated, Upfront)
2021-0618 (chemo RTD): Phase I trial evaluating the safety and tolerability of chemoradiation followed by chemotherapy + dostarlimab for stage IIIC, node positive, endometrial cancer.
Advanced or Recurrent
2024-1497 (Lifileucel (E-TIL): A phase II, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced endometrial cancer.
2022-0751 (Eisai): An open-label phase Ib study of E7386 in combination with other anticancer drug(s) in subjects with solid tumors.
2023-0585 (ComboMATCH): EAY191-N4: A randomized trial of Selumetinib and Olaparib or Selumetinib alone in patients with recurrent or persistent Ras pathway mutant Ovarian and Endometrial cancers.
Cervical, Vaginal, Vulvar
Newly Diagnosed
Recurrent, Metastatic
2022-0107 (Traction): This is a study to learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.
Multiple Solid Tumor Sites
Recurrent, Metastic
2024-2001 (MacroGenics): Phase II multicohort study to evaluate Lorigerlimab in participants with advanced solid tumors.
Surgical Trials
2020-0165: A phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant chemotherapy).
Last updated July 9, 2025
request an appointment online.